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Abstract: In this study, we have explored the possibility of the combination of the high reactivity 
of nano Fe3O4 or Au nanoparticles and daunomycin, one of the most important antitumor drugs 
in the treatment of acute leukemia clinically, to inhibit MDR of K562/A02 cells. Initially, to 
determine whether the magnetic nanoparticle Fe3O4 and Au can facilitate the anticancer drug 
to reverse the resistance of cancer cells, we have explored the cytotoxic effect of daunomycin 
(DNR) with and without the magnetic nano-Fe3O4 or nano-Au on K562 and K562/A02 cells 
by MTT assay. Besides, the intracellular DNR concentration and apoptosis of the K562/A02 
cells was further investigated by ﬂ  ow cytometry and confocal ﬂ  uorescence microscopic studies. 
The MDR1 gene expression of the K562/A02 cells was also studied by RT-PCR method. Our 
results indicate that 5.0 × 10−7 M nano-Fe3O4 or 2.0 × 10−8 M nano-Au is biocompatible and can 
apparently raise the intracellular DNR accumulation of the K562/A02 cells and increase the 
apoptosis of tumor cells. Moreover, our observations illustrate that although these two kinds of 
nanoparticles themselves could not lower the MDR1 gene expression of the K562/A02 cells, 
yet they could degrade the MDR1 gene level when combining with anticancer drug DNR. This 
raises the possibility to combine the nano-Fe3O4 or nano-Au with DNR to reverse the drug 
resistance of K562/A02 cells, which could offer a new strategy for the promising efﬁ  cient 
chemotherapy of the leukemia patients.
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Introduction
It is well known that the tumor cells can become resistance to the chemotherapeutics. 
Multidrug resistance (MDR) has been a major cause leading ﬁ  nal failure of the tumor 
chemotherapy clinically (Bradley et al 1988). MDR is usually characterized by the 
over-expression of P-gp (Litman et al 1997; Soma et al 2000; Ferrao et al 2001) that 
acts as an energy-dependent drug efﬂ  ux pump and leads to a decrease in cytotoxic 
drug accumulation (Hamada and Tsuruo 1988).
Unlike solid tumor, hematological malignant tumor can’t be cured by surgical 
treatment. The main strategy to treat it is chemotherapy. Considering the importance 
of MDR in clinical hematological oncology, various kinds of P-gp-selective antago-
nisms have been developed to reverse P-gp-mediated MDR in vitro or in clinical 
trials. Undoubtedly, the reverse drugs can enhance the sensitization of the tumor 
to different chemotherapeutics in vivo or in vitro and thus resolve MDR to some 
extent (Hegewisch-Becker 1996; Twentyman et al 1992; Advani et al 1999; Tan 
et al 2000). Except some drugs such as tetrandrine (Tet), cyclosporin A (CsA) and 
PSC 833, most P-gp-selective antagonisms can’t be applied in large scale clinically 
because of their serious side effects on the pharmacokinetics of other accompanying 
chemotherapeutic drugs. Much effort has been devoted to the reversal of Tet in our International Journal of Nanomedicine 2008:3(3) 344
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laboratory in recent years and it was veriﬁ  ed that Tet would 
be a potential reversal drugs in vivo and in vitro (Xu et al 
2006). Furthermore, one new strategy of target administering 
by drug carrier systems such as liposome (Alf and Jean-
Pierre 2006), nanoparticle (Cuvier et al 1992; Brigger et al 
2002; Vauthier et al 2003; Jain et al 2005), and others, has 
been developed to enhance the efﬁ  ciency of anticancer drug 
delivery. Nanomaterials are well known to have potential 
applications in various biomedical ﬁ  elds, such as disease 
diagnostics and therapeutics (Farokhzad et al 2005). They 
have attracted more and more attention to reverse MDR 
recently. It was reported that gold nanoparticles had been 
utilized for gene delivery (Sanford et al 1993). Moreover, 
some nanoparticles have been explored to illustrate the 
mechanisms of biochemical modulation and have potentially 
promising use in clinical cancer chemotherapy applications 
(Kirchner et al 2005).
Magnetic nano-Fe3O4 could be used in the biomedicine 
areas because of their biocompatibility, simple prepa-
ration, and other unique properties (Zhang et al 2006; 
Li et al 2007). Fe3O4 nanoparticles were found readily to 
interact with proteins (Chen et al 2002). It is reported that 
the trichloro-s-triazine (TsT) can be used as an easy linker 
to couple magnetic Fe3O4 nanoparticles with hydrophilic 
monomethoxy-poly (ethylene glycol) (mPEG), and the 
mPEG – dopamine-coated nanoparticles were stable in 
buffer at various pH values greater than 7 or at the tempera-
tures ranging from 25 °C to 70 °C. On the basis of these 
observations, it is possible to couple various hydrophilic 
macromolecules, including nucleotides and peptides, to 
iron oxide nanoparticles, which could be used for highly 
sensitive DNA sequence detection (Xie et al 2006) and will 
contribute much to biomedical science.
Our recent reports have demonstrated that some antican-
cer drugs could be readily modiﬁ  ed on some biocompatible 
nanomaterials, which could readily afford the sustained 
drug delivery for the target cancer cell lines and reduce 
the relevant toxicity towards normal cells and tissues 
(Li et al 2007; Lv et al 2008). Thus, in this study, we have 
explored the combination of the high reactivity of nano-
Fe3O4 or Au nanoparticles with daunomycin, one of the 
most important antitumor drugs in the treatment of acute 
leukemia clinically, to inhibit MDR of K562/A02 cells. 
The main point of this strategy is to increase the intracel-
lular concentration of the targeted drug by the synergistic 
effect of nanoparticles. The reverse effects of nano-Fe3O4 
and nano-Au towards K562 and K562/A02 cells have been 
investigated in this report.
Materials and methods
Cell lines and cell culture
K562 cells, derived from human leukemic cells of a chronic 
myeloid leukemia patient in blastic crisis, had been constantly 
preserved in our laboratory. K562/A02 cells (provided by 
Prof. C. Yang, Institute of Hematology, Chinese Academy of 
Medical Sciences and Peking Union Medical College, China) 
were incubated in the medium containing 1 μg/ml ADM for 
maintaining the resistant characteristics. K562/A02 cells 
were kept in medium without ADM for 2 weeks before using 
these cells. Both these two kinds of cell lines were cultured in 
a ﬂ  ask in RPMI 1640 medium (GIBCO, Carlsbad, CA, USA) 
supplemented with 10% fetal calf serum (FCS; GIBCO), 
100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C, 
5% CO2. K562/A02 cells were maintained in a complete 
RPMI 1640 medium containing 1 μg/ml adriamycin, and 
cultured for two weeks in drug-free medium prior to their 
use in each experiment.
Reagents
Daunomycin (DNR) was purchased from Farmitalia (Italian). 
MTT was purchased from Sigma (St. Louis, MO, USA). PCR 
reagents kit was purchased from TaKaLa (China). TRI-zol 
reagent was purchased from Gibco/BRL, USA. MDR1 and 
β-actin primer were synthesized by Shanghai Biotechnology 
Company (China) and Invitrogen (Carlsbad, CA, USA). All 
reagents used in this study are analytical grade.
Preparation of drug-loaded nanoparticles
Nano-Fe3O4 and nano-Au were prepared by the electro-
chemical deposition under oxidizing conditions (EDOC). 
Before applied in the present experiment, the magne-
tite nanoparticles were well-distributed in RPMI 1640 
medium freshly added with 10% heat-inactivated FBS by 
using ultrasound treatment in order to obtain nano-Fe3O4 
and nano-Au colloidal suspension. ADM conjugated with 
nano-Fe3O4 (nano-Fe3O4-ADM) or ADM conjugated with 
nano-Au (nano-Au-ADM) were prepared by mechanical 
absorption polymerization referring to previously reported 
(Gao et al 2004; Bennis et al 1994). We also investigated the 
temperature effect and chose 37 °C or 4 °C for the polym-
erization process. Brieﬂ  y, different concentrations (V/V), 
nano-Fe3O4 and nano-Au were respectively added under 
mechanical stirring to 200 μl of an aqueous medium with 
certain concentration of ADM that in the ﬁ  nal nanoparticle 
and cell suspension was 50 μmol/l (pH 7.4). At different 
temperatures (37 °C, 4 °C), the overall polymerization 
process lasted for 24 h.International Journal of Nanomedicine 2008:3(3) 345
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Cytotoxicity assays
K562 and K562/A02 cells (2 × 104 cells per well) in 
log phase were incubated into 96-well flat-bottomed 
plates (Costar, Charlotte, NC) respectively. Different 
concentrations of DNR, nano-Fe3O4 and nano-Au were 
added into these cells alone and cultured for 48 h to 
measure their cytotoxicity. On the basis of these results, 
different concentrations of DNR, nano-Fe3O4 and nano-
Au were combined to ﬁ  nd the best combination that the 
compound will kill the tumor cells most. After incubation 
for 48 h, MTT solution (20 μl at 5 mg/ml) was added to 
each well and incubated for 4 h, followed by reading the 
optical density value (A) at 540 nm using a plate reader 
(Model 550, BIO-RAD, Japan) to measure the amount of 
cell proliferation and/or killing. The inhibition ratio (IR) 
of cells was determined as follows: (1-A of tests cells/A 
of blank control) ×100%. Each assay was repeated at least 
three times.
DNR accumulation in K562/A02 cells
and K562/A02 cells apoptosis
Brieﬂ  y, 1 × 106 cells were incubated with DNR (10 mg/L) 
in the presence or absence of nano-Fe3O4 (5.0 × 10−7 M) or 
nano-Au (2.0 × 10−8 M). After incubation for 48 h, cells 
were harvested and washed twice in ice-cold PBS and 
the amount of DNR accumulated in K562/A02 cells was 
determined by measuring the cell-associated ﬂ  uorescence 
emission (480 nm) using ﬂ  ow cytometry (FACS Calibar, 
Becton – Dickinson, USA) according to a previously descried 
method (Suzuki et al 1997). Brieﬂ  y, 100 pL cell suspensions 
were treated with 5 pL Annexin V-FITC for 30 min in the 
dark, and the sample were analyzed with ﬂ  ow cytometry. The 
apoptosis of several subgroup K562/A02 cells was measured 
by ﬂ  ow cytometry again to further identify the cytotoxicity 
of DNR with nano-Fe3O4 or nano-Au.
Confocal ﬂ  uorescence microscopic 
studies
50 mg/L DNR and 5.0 × 10−7 M nano-Fe3O4 or 2.0 × 10−8 M 
nano-Au magnetic solution were injected into a cell culture 
for incubation. In a control experiment, only DNR was 
injected into a cell culture for incubation. The culture was 
detected using a confocal ﬂ  uorescence microscope (Leica 
TCS SP2) after incubating for 30 min. The freshly prepared 
cell culture was dropped on a rigorously cleaned glass plate 
immediately before the measurement. The excitation wave-
length of the ﬂ  uorescence was 480 nm.
RT-PCR study
The several subgroup K562/A02 cells (above) were 
centrifuged by 1000 rpm for 5 min and collected. Total 
cellular RNA was extracted using the TRI-zol reagent as 
described by the manufacturer. One microgram of RNA 
was used for cDNA synthesis employing avian myeloblas-
tosis virus (AMV) reverse transcriptase and oligo dT as the 
primer. cDNA was ampliﬁ  ed with speciﬁ  c primers for MDR1. 
β-actin was used as an internal control to conﬁ  rm successful 
cDNA synthesis. For MDR1 and β-actin, the amplify condi-
tions as follows: 94 °C 30 sec, 56 °C 30 sec, 72 °C 1 min, 
30 cycles. Primer sequences were as follows: MDR1 (437 bp) 
sense: 5’-TGG TTT GAT GTG CAC GAT GTT GGG-3’, 
antisense: 5’-AGA TCA GCA GGA AAG CAG CAC CTA-3’, 
β-actin (661 bp) sense: 5’-TGA CGG GGT CAC CCA CAC 
TGT GCC CAT CTA-3’, antisense: 5’-CTA GAA GCA TTT 
GCG GTG GAC GAT GGA GGG -3’ (Tan et al 2003). PCR 
products were separated on 1.5% agarose gels. The band 
intensities on gels photographs were directly quantitated by 
ImagerMaster VDS image analysis (Pharmacia Biotech, USA), 
and the target/control ratios were calculated.
Results
Growth rates of K562 and K562/A02 
cells by MTT assay
We have examined the cytotoxic activity of DNR, nano-Fe3O4 
or nano-Au alone to K562 cells and its Pgp-overexpression 
MDR counterparts-K562/A02. K562/A02 was signiﬁ  cantly 
resistant to DNR: 50% inhibiting concentration (IC50) values 
after incubation for 48 h was 23.23 mg/L, which is 76-fold 
higher than K562 cells, while the IC50 values after incubation 
for 48 h of K562 cells was 0.307 mg/L. The growth inhibition 
curves of two cell lines to DNR were shown in Figure 1. It was 
noted that nano-Fe3O4 or nano-Au themselves alone could hardly 
inhibit K562/A02 and K562 proliferation when their doses 
were between 2.0 × 10−9 M to 1.0 × 10−6 M (P   0.05), which 
also conﬁ  rmed their good biocompatibility. In another experi-
ment, we chose DNR in concentration of 10 mg/L, 20 mg/L, 
and 0.05 mg/L, 0.1 mg/L (smaller than IC50 to K562/A02 and 
K562, respectively) combined with different concentration 
of nano-Fe3O4 or nano-Au to ﬁ  nd the optimum combination 
condition which affected most tumor cells. It was observed that 
nano-Fe3O4 or nano-Au combining with DNR could inhibit two 
cell lines proliferation signiﬁ  cantly (P   0.001). 5.0 × 10−7 M 
nano-Fe3O4 or 2.0 × 10−8 M nano-Au did the best in K562/A02, 
while 2.5 × 10−7 M nano-Fe3O4 or 1.0 × 10−8 M nano-Au did the 
best in K562 (as shown in Figures 2, 3).International Journal of Nanomedicine 2008:3(3) 346
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Tumor cells apoptosis
Based on these observations, it appeared that DNR combin-
ing with nano-Fe3O4 or nano-Au could efﬁ  ciently increase 
the apoptosis ratio of K562/A02 cells. The ﬂ  ow cytometry 
results show that nano-Fe3O4 or nano-Au themselves can 
hardly induce the apoptosis of K562/A02 cells.12.57% 
apoptosis of K562/A02 cells was observed under DNR 
alone, while 32.76% and 29.38% apoptosis of K562/A02 
cells were observed when the K562/A02 cells were treated 
with DNR in combination with nano-Fe3O4 or nano-Au 
(Figure 4).
The intracellular free DNR concentration
The intracellular DNR concentration of the K562/A02 
cells was explored by ﬂ  ow cytometry. Compared with 
that treated with DNR alone, the intracellular DNR con-
centration of the K562/A02 cells were found to increase 
by 71% and 51%, respectively when the K562/A02 cells 
were treated with DNR in combination with nano-Fe3O4 
and nano-Au, respectively. Similar observations were 
also illustrated through confocal ﬂ  uorescent microscope 
(Figure 5). Considering that the anticancer drug dau-
norubicin is a ﬂ  uorescent molecule while the relevant 
nanoparticles have no ﬂ  uorescence, our observations of 
the laser confocal ﬂ  uorescence microscopy further conﬁ  rm 
the synergistic effect of these nanoparticles on the cellular 
uptake of daunorubicin.
RT-PCR
Additionally, our RT-PCR studies showed that these two 
kinds of nanoparticles themselves could not lower the MDR1 
gene expression of the K562/A02 cells, but they could 
down regulate the MDR1 gene level when combined with 
DNR. K562 cells were negative in MDR1 gene expression. 
Computer-assisted image analysis showed that the ratios 
of MDR1/β-actin band intensities were as follows: Nano-
Fe3O4: 0.793 ± 0.03, Nano-Au: 0.770 ± 0.033, Nano-Fe3O4 
with DNR: 0.619 ± 0.034 (P   0.01) and Nano-Au with 
DNR: 0.635 ± 0.041 (P   0.01), where the descent rate 
were 23.3% and 21.6%, respectively (as shown in Table 3 
and Figure 6).
Figure 2 Growth inhibiting rate of daunomycin (DNR) with or without nanoparticle 
treated-K562/A02 cells (48 h).
Notes: P   0.05, compared to DNR without nanoparticle treated-K562/A02 cells 
(single factor analysis of variance); 1P   0.01, compared with DNR without nanoparticle 
treated-K562/A02 cells (single factor analysis of variance).
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Figure 3 Growth inhibiting rate of daunomycin (DNR) with or without nanoparticle 
treated-K562 cells (48 h).
Notes: P   0.05, compared with DNR without nanoparticle treated-K562 cells (single 
factor analysis of variance); 1P   0.01, compared with DNR without nanoparticle 
treated-K562 cells (single factor analysis of variance); 2P   0.05, compared with DNR 
without nanoparticle treated-K562 cells (single factor analysis of variance).
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Figure 1 Effect of the different concentrations of daunomycin (DNR) on growth 
inhibitiom rates of K562/A02 cells (A) and K562 cells (B) by MTT assay.
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Figure 4 The apoptosis of K562/A02 cells under daunomycin (DNR) with and without nanoparticles. K562/A02 cells (A–D) were incubated with Nano-Fe3O4 (5.0 × 10−7 M) 
(B), Nano-Au (2.0 × 10−8 M) (C), DNR (10 mg/L) (D) and nothing (A), respectively, and K562/A02 cells (E–F) were incubated with DNR (10 mg/L) in the presence of Nano-
Fe3O4 (5.0 × 10−7 M) (E) or Nano-Au (2.0 × 10−8 M) (F) at 37 °C for 48 h.International Journal of Nanomedicine 2008:3(3) 348
Chen et al
A
C
B
F
E D
Figure 5 Effect of nanoparticle on the intracellular accumulation of daunomycin (DNR) in K562/A02 cells (×1000). K562/A02 (A–C) and K562 (D–F) cells were incubated 
with DNR (50 mg/L) in the absence (A,D) or the presence of Nano-Fe3O4 (5.0×10−7 M) (B, E) or Nano-Au (2.0 × 10−8 M) (C,F) at 37 °C for 30 min. The cells were observed 
and photographed under a confocal ﬂ  uorescent microscope.International Journal of Nanomedicine 2008:3(3) 349
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Discussion
As described above, we have demonstrated that nanoparticles 
themselves can not reverse MDR-mediated resistance in 
K562/A02 cells, but they did if combined with certain che-
motherapeutics such as DNR. However, it is reported that 
nano-Fe3O4 with better histocompatibililty to human body 
was suitable to prepare some materials imbedded in human 
body (Dresco et al 1999; Du et al 2005). Our observations 
indicate that nanoparticles themselves can not inhibit the 
growth of K562/A02 and K562 cells or induce their apopto-
sis. In our studies, we choose DNR with 10 mg/L or 20 mg/L 
and 0.05 mg/L or 0.1 mg/L to K562/A02 and K562 cells, 
respectively, which are smaller than IC50 of DNR, to combine 
different volume fraction of nanoparticles ranging from 2.0 
× 10−9 M to 1.0 × 10−6 M so that they can interact with each 
other with water-bath at 50 °C for 30 min, following by 
standing to stay overnight. Our observations indicate that the 
presence of nano-Fe3O4 could enhance the cytotoxic effect 
of DNR to K562/A02 and K562 cells, having signiﬁ  cant 
difference with DNR alone group (P   0.05). To K562/A02 
cells, the effective combination, composed by 5.0 × 10−7 M 
nano-Fe3O4 or 2.0 × 10−8 M nano-Au and 10 mg/L DNR, 
could efﬁ  ciently induce more K562/A02 cells apoptosis. 
These results may be attributed to that these nanoparticles 
could readily interact with DNR and form so-called conju-
gated nanocomposites, which could facilitate the cellular 
uptake of DNR and thus enhance the cytotoxic effect of 
K562/A02 cells. MTT and confocal ﬂ  uorescent microscope 
studies also indicate that these functionalized nanoparticle 
could efﬁ  ciently strengthen DNR lethal effect to target cancer 
cells and increase the intracellular accumulation of DNR. 
Meanwhile, we also ﬁ  nd the non-speciﬁ  c cytotoxocity of 
these nanoparticles was similar for both the parent tumor cell 
line and its MDR counterpart (Table 1) which suggests that 
the relevant nanoparticles conjugated with DNR may exert 
its MDR-reversal activity via down-regulation of MDR gene 
transcription of K562/A02 cells.
In summary, we have demonstrated that the functional 
nanoparticles could help DNR entering K562/A02 and K562 
cells and increase the intracellular accumulation of DNR. 
Table 1 The MDR1 mRNA level of K562/A02 cells with nanoparticle in the absence or presence of DNR (at 48 h) (n = 3)
Groups Positive  control  Nano-Fe3O4  Nano-Au  DNR with Nano-Fe3O4  DNR with Nano-Au
MDR1/β-actin 0.809  ± 0.033  0.793 ± 0.037  0.770 ± 0.040  0.619 ± 0.042*  0.635 ± 0.050*
descent rate (%)    1.90 ± 0.069  4.57 ± 0.072  23.33 ± 0.069  21.60 ± 0.035
Notes: *P   0.01, compared with K562/A02 cells (single factor analysis of variance).
Figure 6 The MDR1 mRNA level of K562/A02 cells with nanoparticles (5.0 × 10−7 M Nano-Fe3O4 or 2.0 × 10−8 M Nano-Au) in the absence or presence of DNR (10 mg/L) Lane:1, 
marker; 2, K562 (negative control); 3,K562/A02 (positive control); 4, Nano-Fe3O4; 5, Nano-Au; 6, DNR with Nano-Fe3O4; 7, DNR with Nano-Au.International Journal of Nanomedicine 2008:3(3) 350
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Although the relative mechanisms need to be explored fur-
ther, the conjugated nanocomposites could have promising 
application to inhibit the drug resistant and facilitate the target 
drug delivery in the relevant cancer chemotherapy.
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